MedTrace Logo

A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy

NCT02133911 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-04-28

No results posted yet for this study

Summary

Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave symptoms of angina in patients with stable coronary disease that is not suitable for surgical or percutaneous revascularization. It has been shown that in patients with stable coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in patients with dilated cardiomyopathy.

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

Ranolazine

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Gregor Poglajen, MD, PhD · Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia

  • Bojan Vrtovec, MD, PhD · Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2015-12-15
Completion
2016-04-02

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133911 on ClinicalTrials.gov